Edwards Lifesciences Corporation (Edwards Lifesciences) is focused on technologies that treat structural heart disease and critically ill patients. A pioneer in the development and commercialization of heart valve products, Edwards Lifesciences is the manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. The Company also provides hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The products and technologies provided by Edwards Lifesciences to treat advanced cardiovascular disease or critically ill patients are categorized into three main areas: Surgical Heart Valve Therapy, which combines surgical heart valves and Cardiac Surgery Systems; Transcatheter Heart Valves; and Critical Care, which includes Vascular. In October 2012, it acquired BMEYE B.V.
|Headquarters||One Edwards Way|
IRVINE, CA, United States 92614
|Chairman of the Board, Chief Executive Officer||Michael Mussallem|
|Chief Financial Officer, Corporate Vice President||Thomas Abate|
|Corporate Vice President, General Counsel||Aimee Weisner|
|Corporate Vice President - Human Resources||Christine McCauley|
|Corporate Vice President - Heart Valve Therapy||Donald Bobo|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||113.0M||Book Value||$12.94|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||4.0|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||18.0x|
|Pay Date||1/1/01||Operating Margin||25.78%|
*GAAP = prior to non-GAAP analyst adjusted earnings.